escc
Showing 1 - 5 of 5
Ovarian Cancer, NSCLC, ESCC Trial in United States (ASP0739, Pembrolizumab)
Active, not recruiting
- Ovarian Cancer
- +3 more
-
Duarte, California
- +6 more
Jan 21, 2023
ESCC Trial (Tislelizumab combined with chemoradiotherapy)
Not yet recruiting
- ESCC
- Tislelizumab combined with chemoradiotherapy
- (no location specified)
Sep 18, 2022
ESCC, Adjuvant Treatment, Lymph Node Positive Trial in Tianjin (Pembrolizumab Injection [Keytruda])
Recruiting
- ESCC
- +3 more
- Pembrolizumab Injection [Keytruda]
-
Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Apr 26, 2021
ESCC Trial in Chongqing (TC/PD-1 inhibitor/anlotinib)
Not yet recruiting
- ESCC
- TC/PD-1 inhibitor/anlotinib
-
Chongqing, Chongqing, ChinaDaping Hospital, Third Military Medical University
Jul 12, 2020